Laxacin Tablet
NDC Package 50488-0901-1
Package Information
Laxacin (docusate sodium and sennosides) tablets is take preferably at bedtime or as directly by a doctoragestarting dosemaximum doseadults and children 12 years and older2 tablets once a day4 tablets twice a dayOther informationEach tablet contains: Calcium 20 mgEach tablet contains: Sodium 4 mgStore at room temperatureKeep lid tightly closed in a dry placeDo not use if imprinted safety seal under cap is broken or missing. This formulation utilizes a tablet delivery system. Marketed by Alexso, Inc, this product is identified by NDC 50488-0901 and is authorized under FDA application M007.
Identification & Billing
- RxCUI: 2106884 - Laxacin 50 MG / 8.6 MG Oral Tablet
- RxCUI: 2106884 - docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Laxacin]
- RxCUI: 2106884 - DOSS Sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Laxacin]
- RxCUI: 998740 - sennosides 8.6 MG / docusate sodium 50 MG Oral Tablet
- RxCUI: 998740 - docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50488 - Alexso, Inc
- 50488-0901 - Laxacin
- 50488-0901-1 - 100 TABLET in 1 BOTTLE
- 50488-0901 - Laxacin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50488-0901-1 identifies a specific commercial package of 100 tablet in 1 bottle of Laxacin, a human over the counter drug labeled by Alexso, Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This tablet is formulated for oral use and contains docusate sodium; sennosides a and b as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alexso, Inc on October 15, 2018. The current certification is valid through December 31, 2026.
How is this Alexso, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50488090101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.